New Clinical Data on Urologix' In-Office BPH Therapies Highlighted at Recent AUA Regional Meetings

New Clinical Data on Urologix' In-Office BPH Therapies Highlighted at Recent
AUA Regional Meetings

Urologix' market-leading non-surgical BPH therapies have been well represented
at this year's AUA regional meetings. Most notably, three clinical studies
were presented demonstrating the effectiveness of Prostiva RF Therapy and
Cooled ThermoTherapy.

MINNEAPOLIS, Minn., Nov. 20, 2013 (GLOBE NEWSWIRE) -- via PRWEB - Urologix'
(OTCQB:ULGX) market-leading non-surgical BPH therapies have been well
represented at this year's American Urology Association (AUA) regional
meetings. Most notably, three clinical studies were presented demonstrating
the effectiveness of Prostiva® RF Therapy and Cooled ThermoTherapy™. These
studies' results demonstrate clinical effectiveness in line with prior
publications and build evidence for earlier intervention in BPH disease
progression. In addition, one study demonstrates greater patient comfort using
a modified prostatic block technique. All three posters can be downloaded from
the Urologix website at Both
Prostiva and Cooled ThermoTherapy are indicated for the treatment of Benign
Prostatic Hyperplasia (BPH) and are included in the AUA Guidelines for
management of BPH. In-Office BPH Therapy is an excellent treatment alternative
for the countless patients suffering from an enlarged prostate who do not want
or are not doing well on BPH medications.

Dr. Craig Smith, a board certified urologist at DuPage Medical Group Urology
in Chicago, presented the poster "Painless In-Office Prostiva" at the 2013
North Central Section AUA Meeting. The study was independently funded by
DuPage Medical Group and measured intra-procedure comfort levels of 45
patients after administering a modified version of a typical prostatic block,
a procedure where local anesthetic is injected into the prostate area prior to
a medical procedure. Using a validated visual analog pain scale of 0-10, all
patients reported scores of 2 or less with 87% reporting no pain at all.
Following the procedure, the patients demonstrated symptom score improvement
of 69% at 2 years. Dr. Smith concluded that with better patient comfort
controls in place, a physician is able to treat more sites on the prostate
which may result in improved outcomes and longer duration of the sustained

To view a video on performing a modified prostatic block similar to the one
Dr. Smith utilized, please visit the Urologix Physician Resource Center at

In a study co-authored by Dr. Parminder Sethi, a retrospective analysis of 51
patients was performed to quantify subjective and objective improvement in
patients who chose Prostiva RF Therapy. The results of this analysis were
presented at the 2013 Western Section AUA Meeting during the prostate and
bladder poster session. This analysis showed a significant improvement of 68%
at 1 year which was well maintained in patients reaching the 2 year follow-up
time point. It also demonstrated that 7 of the 8 patients in retention prior
to the treatment were free from retention after having Prostiva RF Therapy.

"For me, the results of this retrospective analysis confirm both the initial
symptom improvement patients can expect from Prostiva, as well as the
long-term relief from BPH." stated Parminder Sethi, co-author of the
retrospective analysis.

Finally, a study by Drs. Cox, Smith, Conlin and Hatch, sponsored by the
Portland VA Medical Center, evaluated Cooled ThermoTherapy in veterans, many
of whom presented later in disease progression and typically were considered
higher risk. In this prospective study, 101 consecutive patients were treated
using Cooled ThermoTherapy including 64% of patients in retention. Of those in
retention, 56% were free of retreatment or intermittent self-catheterization
post treatment. Markedly, those patients not in retention prior to the
procedure saw a much higher 86% freedom from retreatment and
self-catheterization. The strong correlation between greater freedom from
retreatment and retention and earlier intervention suggests that while chronic
retention patients receive benefit from Cooled ThermoTherapy, earlier
intervention produces a higher success rate and greater durability.

"The entire team at Urologix is very proud to see the positive impact on
patients' lives our customers are achieving through the use of our
technologies and thank them for their efforts to publish their results."
stated Greg Fluet, CEO of Urologix. "It was especially compelling to see data
from the Portland Veterans Administration where the patients are so deserving
of the best care our country can provide. It is our hope that data of this
sort showing the benefits of earlier intervention will help increase access to
care for both veterans and non-veterans alike as so many men are stuck on
chronic medication for years before understanding what alternative options

About Urologix

Urologix, Inc., based in Minneapolis, develops, manufactures, markets and
distributes minimally invasive medical products for the treatment of
obstruction and symptoms due to Benign Prostatic Hyperplasia (BPH). Urologix'
Cooled ThermoTherapy™ produces targeted microwave energy combined with a
unique cooling mechanism to protect healthy tissue and enhance patient
comfort. The Prostiva® RF Therapy System is an anatomical approach which uses
radio frequency energy to destroy the prostate tissue, reducing constriction
of the urethra, and thereby relieving BPH symptoms. Both of these therapies
provide safe, effective and lasting relief of obstruction and symptoms due to
BPH. Prostiva is a registered trademark of Medtronic, Inc., used under
license. All other trademarks are the property of Urologix.

Federal USA law restricts these devices to sale by or on the order of a
physician. For more complete information about the benefits, risks and
contraindications associated with Cooled ThermoTherapy and Prostiva RF
Therapy, please refer to

If you would like more information on this topic, please contact Karen Snay at
513-484-2987 or ksnay(at)urologix(dot)com.

The Urologix logo and other media assets are available at

Urologix Media Contact

Karen Snay

(513) 484-2987

Urologix Investor Relations Contact

Brian Smrdel

(763) 475-7696

This article was originally distributed on PRWeb. For the original version
including any supplementary images or video, visit

CONTACT: Urologix, Inc.
         Karen Snay
         +1 5134842987
Press spacebar to pause and continue. Press esc to stop.